Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
Provided By GlobeNewswire
Last update: Jan 13, 2025
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –
Read more at globenewswire.com
